Posted by Michael Wonder on 30 Jul 2023
PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist
29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the most serious breast cancer, triple negative breast cancer.
The drug buying agency says it will take applications to fund Keytruda for triple negative breast cancer to a Cancer Treatments Advisory Committee meeting in October.
But the Breast Cancer Foundation says action is needed now because the evidence for Keytruda for the triple negative cancer strain is “undisputable .. proven and effective.”
